Cellares, an integrated development and manufacturing organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc., a clinical-stage biotechnology company developing targeted cell therapies for autoimmune diseases, reported that Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle, through Cellares’ technology adoption partnership (TAP) program. The companies have agreed on a proof-of-concept technology transfe...